| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arteriovenous Shunt, Surgical | 7 | 2021 | 25 | 2.550 |
Why?
|
| Blood Vessel Prosthesis Implantation | 14 | 2020 | 36 | 2.460 |
Why?
|
| Aortic Aneurysm, Abdominal | 10 | 2022 | 24 | 1.950 |
Why?
|
| Endovascular Procedures | 8 | 2022 | 70 | 1.890 |
Why?
|
| Arteriovenous Fistula | 3 | 2021 | 16 | 1.590 |
Why?
|
| Vascular Surgical Procedures | 12 | 2021 | 54 | 1.440 |
Why?
|
| Peripheral Arterial Disease | 5 | 2025 | 137 | 1.370 |
Why?
|
| Muscle, Smooth, Vascular | 10 | 2015 | 77 | 1.270 |
Why?
|
| Femoral Artery | 7 | 2014 | 58 | 1.190 |
Why?
|
| Lower Extremity | 7 | 2021 | 84 | 1.180 |
Why?
|
| Frailty | 3 | 2021 | 19 | 1.030 |
Why?
|
| Amputation | 4 | 2021 | 42 | 1.030 |
Why?
|
| Stents | 9 | 2017 | 121 | 0.980 |
Why?
|
| Treatment Outcome | 25 | 2025 | 2380 | 0.790 |
Why?
|
| Postoperative Complications | 5 | 2021 | 613 | 0.770 |
Why?
|
| Thrombomodulin | 3 | 2015 | 10 | 0.770 |
Why?
|
| Venous Thromboembolism | 2 | 2022 | 133 | 0.760 |
Why?
|
| Time Factors | 22 | 2021 | 1593 | 0.740 |
Why?
|
| Humans | 66 | 2025 | 28121 | 0.740 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 98 | 0.740 |
Why?
|
| Geriatric Assessment | 2 | 2021 | 88 | 0.720 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 126 | 0.720 |
Why?
|
| Vascular Patency | 12 | 2021 | 44 | 0.710 |
Why?
|
| Retrospective Studies | 19 | 2022 | 2557 | 0.700 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 44 | 0.640 |
Why?
|
| Aged | 28 | 2022 | 5416 | 0.620 |
Why?
|
| Peripheral Vascular Diseases | 4 | 2018 | 64 | 0.600 |
Why?
|
| Male | 39 | 2022 | 13487 | 0.590 |
Why?
|
| Intermittent Claudication | 3 | 2014 | 117 | 0.580 |
Why?
|
| Leg | 6 | 2008 | 134 | 0.570 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2021 | 22 | 0.560 |
Why?
|
| Female | 35 | 2022 | 15156 | 0.550 |
Why?
|
| Angioplasty | 6 | 2018 | 12 | 0.530 |
Why?
|
| Aged, 80 and over | 15 | 2021 | 2021 | 0.530 |
Why?
|
| United States | 9 | 2025 | 2149 | 0.520 |
Why?
|
| Risk Factors | 10 | 2025 | 2084 | 0.520 |
Why?
|
| Saphenous Vein | 9 | 2004 | 24 | 0.500 |
Why?
|
| Arterial Occlusive Diseases | 3 | 2007 | 44 | 0.500 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2015 | 38 | 0.500 |
Why?
|
| Internship and Residency | 4 | 2021 | 239 | 0.490 |
Why?
|
| Limb Salvage | 3 | 2025 | 21 | 0.490 |
Why?
|
| Cell Movement | 11 | 2015 | 369 | 0.490 |
Why?
|
| Ribs | 1 | 2015 | 3 | 0.480 |
Why?
|
| Clavicle | 1 | 2015 | 5 | 0.480 |
Why?
|
| Osteotomy | 1 | 2015 | 24 | 0.470 |
Why?
|
| Decompression, Surgical | 1 | 2015 | 76 | 0.440 |
Why?
|
| Phosphodiesterase 3 Inhibitors | 1 | 2014 | 1 | 0.440 |
Why?
|
| Tetrazoles | 1 | 2014 | 9 | 0.440 |
Why?
|
| Neoplasms | 1 | 2022 | 818 | 0.420 |
Why?
|
| Aorta, Thoracic | 3 | 2010 | 55 | 0.410 |
Why?
|
| Ischemia | 7 | 2020 | 84 | 0.400 |
Why?
|
| Wounds, Nonpenetrating | 2 | 2010 | 52 | 0.400 |
Why?
|
| Arteriosclerosis | 2 | 2003 | 29 | 0.390 |
Why?
|
| Endarterectomy | 2 | 2002 | 4 | 0.380 |
Why?
|
| Risk Assessment | 6 | 2025 | 611 | 0.370 |
Why?
|
| Middle Aged | 21 | 2021 | 7164 | 0.360 |
Why?
|
| Blood Vessel Prosthesis | 7 | 2020 | 28 | 0.340 |
Why?
|
| Platelet-Derived Growth Factor | 7 | 2004 | 26 | 0.340 |
Why?
|
| Extracellular Matrix Proteins | 4 | 2004 | 28 | 0.330 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2021 | 70 | 0.320 |
Why?
|
| Surgeons | 2 | 2022 | 50 | 0.310 |
Why?
|
| Polytetrafluoroethylene | 2 | 2006 | 8 | 0.310 |
Why?
|
| General Surgery | 2 | 2021 | 55 | 0.300 |
Why?
|
| Renal Dialysis | 4 | 2021 | 52 | 0.300 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 475 | 0.300 |
Why?
|
| Veins | 4 | 2019 | 19 | 0.290 |
Why?
|
| Angioplasty, Balloon | 2 | 2007 | 21 | 0.290 |
Why?
|
| Computational Biology | 2 | 2007 | 155 | 0.270 |
Why?
|
| Popliteal Artery | 1 | 2006 | 10 | 0.260 |
Why?
|
| Education, Medical, Graduate | 2 | 2017 | 108 | 0.260 |
Why?
|
| Aneurysm | 1 | 2006 | 25 | 0.260 |
Why?
|
| Genomics | 1 | 2007 | 123 | 0.260 |
Why?
|
| Databases, Factual | 4 | 2019 | 255 | 0.250 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2012 | 163 | 0.250 |
Why?
|
| Hospital Mortality | 2 | 2021 | 149 | 0.250 |
Why?
|
| Suture Techniques | 3 | 2014 | 29 | 0.250 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 215 | 0.250 |
Why?
|
| Proteomics | 1 | 2007 | 181 | 0.240 |
Why?
|
| Patient Readmission | 3 | 2021 | 103 | 0.240 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2015 | 477 | 0.240 |
Why?
|
| Iliac Artery | 2 | 2002 | 19 | 0.240 |
Why?
|
| Aortic Aneurysm, Thoracic | 3 | 2012 | 6 | 0.240 |
Why?
|
| Job Satisfaction | 2 | 2022 | 24 | 0.240 |
Why?
|
| Tunica Intima | 2 | 2004 | 9 | 0.230 |
Why?
|
| Health Services, Indigenous | 1 | 2025 | 16 | 0.230 |
Why?
|
| Patient Preference | 2 | 2022 | 31 | 0.230 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 92 | 0.210 |
Why?
|
| Prosthesis Design | 4 | 2014 | 87 | 0.210 |
Why?
|
| Hemorrhage | 2 | 2020 | 265 | 0.210 |
Why?
|
| Primary Health Care | 1 | 2025 | 152 | 0.210 |
Why?
|
| Decision Support Techniques | 2 | 2022 | 50 | 0.210 |
Why?
|
| Frail Elderly | 2 | 2020 | 15 | 0.210 |
Why?
|
| Hyperlipidemias | 1 | 2003 | 37 | 0.210 |
Why?
|
| DNA | 2 | 2002 | 372 | 0.200 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 454 | 0.200 |
Why?
|
| Aortic Diseases | 3 | 2010 | 16 | 0.200 |
Why?
|
| Inflammation | 1 | 2007 | 626 | 0.200 |
Why?
|
| Arteries | 3 | 2018 | 65 | 0.200 |
Why?
|
| Diabetes Mellitus | 1 | 2025 | 215 | 0.190 |
Why?
|
| Reading | 1 | 2021 | 18 | 0.190 |
Why?
|
| Hospital Costs | 1 | 2001 | 29 | 0.190 |
Why?
|
| Transfection | 1 | 2002 | 318 | 0.180 |
Why?
|
| Plant Leaves | 1 | 2021 | 57 | 0.180 |
Why?
|
| Hemostatic Techniques | 2 | 2014 | 14 | 0.180 |
Why?
|
| Heart-Assist Devices | 1 | 2001 | 30 | 0.180 |
Why?
|
| Burnout, Professional | 1 | 2021 | 21 | 0.180 |
Why?
|
| Focal Adhesion Kinase 1 | 2 | 2020 | 8 | 0.180 |
Why?
|
| Aortography | 2 | 2014 | 6 | 0.180 |
Why?
|
| Cells, Cultured | 10 | 2004 | 985 | 0.170 |
Why?
|
| Angioscopy | 1 | 2000 | 2 | 0.170 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2021 | 72 | 0.170 |
Why?
|
| Length of Stay | 4 | 2010 | 232 | 0.170 |
Why?
|
| Wrist | 1 | 2020 | 8 | 0.170 |
Why?
|
| Forearm | 1 | 2020 | 39 | 0.170 |
Why?
|
| Radial Artery | 1 | 2020 | 21 | 0.170 |
Why?
|
| Physicians | 1 | 2021 | 82 | 0.170 |
Why?
|
| src-Family Kinases | 1 | 2020 | 71 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2020 | 64 | 0.160 |
Why?
|
| Capillary Permeability | 1 | 2020 | 53 | 0.160 |
Why?
|
| Endarterectomy, Carotid | 1 | 2019 | 11 | 0.160 |
Why?
|
| Vascular Remodeling | 1 | 2019 | 14 | 0.160 |
Why?
|
| Kidney Failure, Chronic | 1 | 2020 | 69 | 0.160 |
Why?
|
| Vascular Grafting | 1 | 2019 | 11 | 0.160 |
Why?
|
| Prospective Studies | 5 | 2019 | 1249 | 0.160 |
Why?
|
| Microvessels | 1 | 2020 | 87 | 0.160 |
Why?
|
| Phlebography | 2 | 2019 | 20 | 0.160 |
Why?
|
| Carotid Artery Diseases | 1 | 2019 | 37 | 0.160 |
Why?
|
| Medicine | 1 | 2019 | 22 | 0.160 |
Why?
|
| Clinical Competence | 3 | 2017 | 229 | 0.160 |
Why?
|
| Models, Educational | 2 | 2017 | 23 | 0.160 |
Why?
|
| Cell Survival | 2 | 2015 | 407 | 0.150 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1998 | 31 | 0.150 |
Why?
|
| Multivariate Analysis | 3 | 2010 | 300 | 0.150 |
Why?
|
| Reoperation | 3 | 2015 | 145 | 0.150 |
Why?
|
| Lichens | 1 | 2018 | 1 | 0.150 |
Why?
|
| Chemotaxis | 5 | 1998 | 28 | 0.150 |
Why?
|
| Kidney | 1 | 2020 | 285 | 0.140 |
Why?
|
| Surveys and Questionnaires | 5 | 2022 | 969 | 0.140 |
Why?
|
| Punctures | 2 | 2008 | 17 | 0.140 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 968 | 0.140 |
Why?
|
| Treatment Failure | 3 | 2018 | 69 | 0.140 |
Why?
|
| Follow-Up Studies | 7 | 2007 | 1014 | 0.140 |
Why?
|
| Specialization | 1 | 2017 | 19 | 0.140 |
Why?
|
| Laparotomy | 1 | 2017 | 30 | 0.140 |
Why?
|
| Endoleak | 1 | 2017 | 1 | 0.140 |
Why?
|
| Abdomen | 1 | 2017 | 42 | 0.140 |
Why?
|
| Viscera | 1 | 2017 | 18 | 0.140 |
Why?
|
| Phenotype | 2 | 2018 | 679 | 0.140 |
Why?
|
| Aortic Aneurysm | 1 | 2017 | 15 | 0.130 |
Why?
|
| Carbon | 1 | 2018 | 108 | 0.130 |
Why?
|
| Monocytes | 1 | 2018 | 135 | 0.130 |
Why?
|
| Endothelium, Vascular | 4 | 2020 | 325 | 0.130 |
Why?
|
| Curriculum | 3 | 2017 | 291 | 0.130 |
Why?
|
| Angiography | 4 | 2006 | 35 | 0.130 |
Why?
|
| Thrombin | 1 | 2015 | 69 | 0.120 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2014 | 129 | 0.120 |
Why?
|
| Cell Culture Techniques | 1 | 2015 | 116 | 0.120 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2006 | 70 | 0.110 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 145 | 0.110 |
Why?
|
| Adult | 8 | 2020 | 7757 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 46 | 0.110 |
Why?
|
| Embolization, Therapeutic | 2 | 2006 | 47 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2014 | 47 | 0.100 |
Why?
|
| Cluster Analysis | 2 | 2018 | 124 | 0.100 |
Why?
|
| Surgical Wound Infection | 2 | 2019 | 105 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 107 | 0.100 |
Why?
|
| Vena Cava Filters | 1 | 2012 | 11 | 0.100 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 413 | 0.100 |
Why?
|
| Prosthesis Implantation | 1 | 2012 | 26 | 0.100 |
Why?
|
| Laparoscopy | 2 | 2006 | 146 | 0.100 |
Why?
|
| Recombinant Proteins | 3 | 2004 | 413 | 0.090 |
Why?
|
| Recovery of Function | 3 | 2008 | 118 | 0.090 |
Why?
|
| Logistic Models | 2 | 2011 | 407 | 0.090 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2012 | 191 | 0.090 |
Why?
|
| Databases as Topic | 1 | 2011 | 22 | 0.090 |
Why?
|
| International Classification of Diseases | 1 | 2010 | 36 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2007 | 192 | 0.080 |
Why?
|
| Hyperplasia | 3 | 2007 | 27 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 633 | 0.080 |
Why?
|
| Exercise | 1 | 2014 | 482 | 0.080 |
Why?
|
| Hospitalization | 1 | 2010 | 202 | 0.080 |
Why?
|
| Blood Loss, Surgical | 2 | 2007 | 53 | 0.080 |
Why?
|
| Life Tables | 3 | 2006 | 6 | 0.080 |
Why?
|
| Education, Medical | 1 | 2009 | 66 | 0.080 |
Why?
|
| Amputation Stumps | 1 | 2008 | 3 | 0.080 |
Why?
|
| Learning | 1 | 2009 | 97 | 0.080 |
Why?
|
| Smoking Cessation | 1 | 2014 | 408 | 0.070 |
Why?
|
| Students, Medical | 1 | 2009 | 96 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2007 | 451 | 0.070 |
Why?
|
| Catheterization, Peripheral | 1 | 2008 | 24 | 0.070 |
Why?
|
| Patient Selection | 3 | 2019 | 148 | 0.070 |
Why?
|
| Health Care Costs | 1 | 2008 | 51 | 0.070 |
Why?
|
| Wound Healing | 1 | 2008 | 125 | 0.070 |
Why?
|
| Polyethylenes | 1 | 2007 | 1 | 0.070 |
Why?
|
| Bandages | 1 | 2007 | 14 | 0.070 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2007 | 16 | 0.070 |
Why?
|
| Hemostasis, Surgical | 1 | 2007 | 7 | 0.070 |
Why?
|
| Principal Component Analysis | 1 | 2007 | 51 | 0.070 |
Why?
|
| Polyesters | 1 | 2007 | 36 | 0.070 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2004 | 73 | 0.070 |
Why?
|
| Workload | 2 | 2017 | 38 | 0.070 |
Why?
|
| Iliac Aneurysm | 1 | 2006 | 8 | 0.070 |
Why?
|
| Carotid Arteries | 1 | 2007 | 54 | 0.070 |
Why?
|
| Stomach | 1 | 2006 | 43 | 0.070 |
Why?
|
| Protein Kinase C | 2 | 1997 | 73 | 0.070 |
Why?
|
| Isoenzymes | 2 | 1997 | 86 | 0.070 |
Why?
|
| Endoscopy | 1 | 2007 | 56 | 0.060 |
Why?
|
| Device Approval | 1 | 2006 | 6 | 0.060 |
Why?
|
| Tibial Arteries | 2 | 2003 | 3 | 0.060 |
Why?
|
| Equipment Failure Analysis | 1 | 2006 | 37 | 0.060 |
Why?
|
| Postoperative Care | 1 | 2006 | 68 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2006 | 45 | 0.060 |
Why?
|
| Radiography | 1 | 2006 | 202 | 0.060 |
Why?
|
| Research Design | 1 | 2007 | 182 | 0.060 |
Why?
|
| Preoperative Care | 2 | 2003 | 82 | 0.060 |
Why?
|
| Calcium Channels, T-Type | 1 | 2004 | 2 | 0.060 |
Why?
|
| Egtazic Acid | 1 | 2004 | 10 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 281 | 0.060 |
Why?
|
| Microscopy, Electron | 1 | 2004 | 94 | 0.060 |
Why?
|
| Graft Survival | 2 | 2001 | 29 | 0.050 |
Why?
|
| Rabbits | 1 | 2004 | 276 | 0.050 |
Why?
|
| Hand | 2 | 2020 | 26 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2003 | 7 | 0.050 |
Why?
|
| Rats | 3 | 2020 | 1564 | 0.050 |
Why?
|
| Massachusetts | 1 | 2003 | 16 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2020 | 1433 | 0.050 |
Why?
|
| Cell Division | 3 | 1998 | 154 | 0.050 |
Why?
|
| Quality of Life | 1 | 2007 | 491 | 0.050 |
Why?
|
| Risk | 1 | 2003 | 136 | 0.050 |
Why?
|
| Animals | 5 | 2020 | 10399 | 0.050 |
Why?
|
| Lac Operon | 1 | 2002 | 4 | 0.050 |
Why?
|
| Microinjections | 1 | 2002 | 14 | 0.050 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2002 | 12 | 0.050 |
Why?
|
| beta-Galactosidase | 1 | 2002 | 24 | 0.050 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2002 | 20 | 0.050 |
Why?
|
| Thrombosis | 1 | 2004 | 149 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2012 | 886 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2002 | 57 | 0.050 |
Why?
|
| Health Care Surveys | 2 | 2012 | 66 | 0.050 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2002 | 50 | 0.050 |
Why?
|
| Culture Media | 1 | 2002 | 98 | 0.050 |
Why?
|
| Pressure | 1 | 2002 | 90 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2002 | 136 | 0.050 |
Why?
|
| Femoral Vein | 1 | 2001 | 13 | 0.050 |
Why?
|
| Knee | 1 | 2001 | 25 | 0.050 |
Why?
|
| Medical Staff, Hospital | 1 | 2021 | 22 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2020 | 575 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 1998 | 12 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 39 | 0.050 |
Why?
|
| Calcium | 2 | 2004 | 235 | 0.050 |
Why?
|
| Career Choice | 1 | 2021 | 53 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 242 | 0.040 |
Why?
|
| Foot | 1 | 2000 | 23 | 0.040 |
Why?
|
| Cell Line | 2 | 2020 | 694 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2000 | 34 | 0.040 |
Why?
|
| Biodiversity | 1 | 2021 | 112 | 0.040 |
Why?
|
| Radiation Exposure | 1 | 2020 | 17 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 1998 | 267 | 0.040 |
Why?
|
| Radiography, Interventional | 1 | 2020 | 15 | 0.040 |
Why?
|
| Gene Expression | 1 | 2002 | 414 | 0.040 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 1997 | 29 | 0.040 |
Why?
|
| Cell Adhesion | 2 | 1998 | 138 | 0.040 |
Why?
|
| Mesentery | 1 | 2020 | 10 | 0.040 |
Why?
|
| Catheterization | 1 | 2020 | 50 | 0.040 |
Why?
|
| Intravital Microscopy | 1 | 2020 | 10 | 0.040 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2020 | 24 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2020 | 50 | 0.040 |
Why?
|
| Minority Groups | 1 | 2020 | 70 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 24 | 0.040 |
Why?
|
| Cardiovascular Agents | 1 | 2019 | 22 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 63 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 480 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 198 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 256 | 0.040 |
Why?
|
| Health Status | 1 | 2019 | 148 | 0.040 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2018 | 12 | 0.040 |
Why?
|
| African Americans | 1 | 2020 | 350 | 0.040 |
Why?
|
| Climate | 1 | 2018 | 33 | 0.040 |
Why?
|
| Flavonoids | 1 | 1998 | 33 | 0.040 |
Why?
|
| Prevalence | 1 | 2019 | 494 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2018 | 100 | 0.040 |
Why?
|
| Cell Count | 1 | 1998 | 86 | 0.040 |
Why?
|
| Forests | 1 | 2018 | 35 | 0.040 |
Why?
|
| Biomass | 1 | 2018 | 86 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 76 | 0.040 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 1997 | 7 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2018 | 98 | 0.030 |
Why?
|
| Aneurysm, False | 2 | 2008 | 19 | 0.030 |
Why?
|
| Learning Curve | 1 | 2017 | 13 | 0.030 |
Why?
|
| Integrins | 1 | 1997 | 29 | 0.030 |
Why?
|
| Climate Change | 1 | 2018 | 74 | 0.030 |
Why?
|
| RNA | 1 | 2018 | 111 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 27 | 0.030 |
Why?
|
| Lung | 1 | 2020 | 375 | 0.030 |
Why?
|
| Accreditation | 1 | 2017 | 36 | 0.030 |
Why?
|
| Florida | 1 | 2017 | 54 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2020 | 362 | 0.030 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2017 | 41 | 0.030 |
Why?
|
| Virulence Factors, Bordetella | 1 | 1996 | 5 | 0.030 |
Why?
|
| Cholera Toxin | 1 | 1996 | 6 | 0.030 |
Why?
|
| Second Messenger Systems | 1 | 1996 | 13 | 0.030 |
Why?
|
| Pertussis Toxin | 1 | 1996 | 7 | 0.030 |
Why?
|
| Stimulation, Chemical | 1 | 1996 | 32 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1997 | 94 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1996 | 31 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2017 | 167 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 1996 | 46 | 0.030 |
Why?
|
| Cell Cycle | 1 | 1997 | 161 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 1996 | 242 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 2017 | 163 | 0.030 |
Why?
|
| Obesity | 1 | 2021 | 668 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 1461 | 0.030 |
Why?
|
| Anastomosis, Surgical | 2 | 2007 | 37 | 0.030 |
Why?
|
| Equipment Design | 2 | 2007 | 217 | 0.030 |
Why?
|
| Drug Utilization Review | 1 | 2012 | 7 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2012 | 28 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2012 | 34 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 46 | 0.020 |
Why?
|
| Device Removal | 1 | 2012 | 30 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 223 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2012 | 93 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 2731 | 0.020 |
Why?
|
| Warfarin | 1 | 2012 | 94 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 207 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 3123 | 0.020 |
Why?
|
| Elective Surgical Procedures | 1 | 2012 | 70 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2012 | 94 | 0.020 |
Why?
|
| Aspirin | 1 | 2012 | 124 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2012 | 294 | 0.020 |
Why?
|
| Time Management | 1 | 2009 | 3 | 0.020 |
Why?
|
| Personal Autonomy | 1 | 2009 | 15 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2009 | 128 | 0.020 |
Why?
|
| Aneurysm, Dissecting | 1 | 2008 | 12 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 112 | 0.020 |
Why?
|
| Communication | 1 | 2009 | 181 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2008 | 109 | 0.020 |
Why?
|
| Occlusive Dressings | 1 | 2007 | 2 | 0.020 |
Why?
|
| Reperfusion | 1 | 2007 | 7 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 34 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 58 | 0.020 |
Why?
|
| Operating Rooms | 1 | 2007 | 19 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2007 | 21 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 2007 | 28 | 0.020 |
Why?
|
| Buttocks | 1 | 2006 | 7 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 66 | 0.020 |
Why?
|
| Mesenteric Artery, Inferior | 1 | 2006 | 1 | 0.020 |
Why?
|
| Ligation | 1 | 2006 | 40 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2008 | 722 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2007 | 193 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2006 | 289 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 543 | 0.020 |
Why?
|
| Incidence | 1 | 2006 | 562 | 0.010 |
Why?
|
| Calcimycin | 1 | 2004 | 12 | 0.010 |
Why?
|
| Ionophores | 1 | 2004 | 6 | 0.010 |
Why?
|
| Ion Transport | 1 | 2004 | 11 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2004 | 22 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2003 | 45 | 0.010 |
Why?
|
| Electron Probe Microanalysis | 1 | 2002 | 2 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2007 | 663 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 2002 | 12 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2002 | 40 | 0.010 |
Why?
|
| Protein C | 1 | 2002 | 38 | 0.010 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2002 | 24 | 0.010 |
Why?
|
| Physical Stimulation | 1 | 2002 | 72 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2002 | 69 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2002 | 54 | 0.010 |
Why?
|
| Models, Animal | 1 | 2002 | 128 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 257 | 0.010 |
Why?
|
| Reference Values | 1 | 2001 | 200 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2001 | 210 | 0.010 |
Why?
|
| Cattle | 1 | 2002 | 389 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 773 | 0.010 |
Why?
|
| Contrast Media | 1 | 2001 | 97 | 0.010 |
Why?
|
| Pneumoperitoneum, Artificial | 1 | 2000 | 4 | 0.010 |
Why?
|
| Dissection | 1 | 2000 | 20 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 521 | 0.010 |
Why?
|
| Protein Kinase C-alpha | 1 | 1997 | 9 | 0.010 |
Why?
|
| Protein Kinase C-delta | 1 | 1997 | 6 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1997 | 112 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1997 | 67 | 0.010 |
Why?
|
| Tensins | 1 | 1996 | 2 | 0.010 |
Why?
|
| Isomerism | 1 | 1996 | 12 | 0.010 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 1996 | 8 | 0.010 |
Why?
|
| Benzophenanthridines | 1 | 1996 | 8 | 0.010 |
Why?
|
| Alkaloids | 1 | 1996 | 16 | 0.010 |
Why?
|
| Phenanthridines | 1 | 1996 | 12 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 1996 | 25 | 0.010 |
Why?
|
| Microfilament Proteins | 1 | 1996 | 28 | 0.010 |
Why?
|
| Tyrosine | 1 | 1996 | 92 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 1996 | 66 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1996 | 97 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1996 | 123 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1997 | 270 | 0.010 |
Why?
|
| Receptor, Insulin | 1 | 1996 | 94 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1996 | 249 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 1996 | 185 | 0.010 |
Why?
|